Significance Statement
Obesity is a concerning health issue, and has doubled in more than 70
countries, resulting in escalation of obesity-related disease like type
2 diabetes (T2D). The adiponectin receptors (AdipoR1 and AdipoR2) have
emerged as important targets for controlling inflammation, obesity and
T2D. To maximize the potential of adiponectin receptors in targeting the
fundamental etiopathology of obesity and T2D, we have designed,
synthesized, Adiponectin receptor agonist named AdipoAI (standing for
anti-inflammation) which in our pre-clinical trials on high fat diet
(HFD) observed reduced glucose resistance, insulin tolerance, promoted
adiponectin signaling in liver and adipose tissues of obese mice, and
resulted decrease liver inflammation. Thus, our trial has affirmed,
AdipoAI as a potent agonist of adiponectin with anti-diabetic,
hepatoprotective, anti-inflammatory features.